Atlas Trials

A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Parkinson's Disease Mild Cognitive Impairment (PD-MCI)

Clinical trial NCT04476017 · COMPLETED

Trial details

NCT number
NCT04476017
Sponsor
Supernus Pharmaceuticals, Inc.
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Parkinson DiseaseCognitive Dysfunction
Start date
2020-07-31
Primary completion
2022-03-25
Enrollment
18

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.